A major pharmaceutical company is taking legal action against several telehealth companies for allegedly selling unauthorized versions of a popular weight loss drug. This drug, known for its active ingredient, has been in high demand. The company behind the drug, Eli Lilly, is suing four telehealth firms. These firms are accused of selling copies of the drug made by ...

Eli Lilly has just announced a massive investment of $27 billion to construct four new manufacturing sites across the U. S. This move is driven by the surging demand for their popular weight loss and diabetes injections, as well as their plans to develop new drugs for various conditions. This investment comes at a time when many companies are trying to win favor with...

Eli Lilly, a company based in Indianapolis, recently faced a blow when its stock prices dipped. The reason? Their weight-loss drugs, Zepbound and Mounjaro, didn't sell as well as expected. The company predicted they'd make about $13. 5 billion in the December quarter, which is less than what experts thought. Specifically, Mounjaro made $3. 5 billion, and Zepbound mad...

The U. S. healthcare sector has been through a rough patch since the presidential election, with stocks like Danaher and Eli Lilly taking a hit. This uncertainty stems from President-elect Trump's choice for the Secretary of Health and Human Services, Robert F. Kennedy Jr. , known for his skepticism towards vaccines and obesity drugs. However, this uncertainty can pr...

Eli Lilly's recent earnings report wasn't great, with stocks falling after missing growth targets. But don't panic just yet. The dip could be a chance to buy. Think of it like a rollercoaster: there are ups and downs, but the long-term view is what counts. The company had a messy quarter, but it's also investing heavily in the future. They're trying to meet the high ...

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it...

The US Department of Interior has set an auction date of October 29th for the first-ever sale of offshore wind energy leases in the Gulf of Maine. This significant move marks a major step forward in the country's efforts to transition to cleaner, renewable energy sources. The auction, which includes eight lease areas totaling 830,000 developable acres, has the potent...

Coinbase and MicroStrategy, two prominent players in the cryptocurrency space, recently released their earnings reports, offering a glimpse into the financial health of these companies. At first glance, it appears that Coinbase has beaten revenue expectations, while MicroStrategy reported a loss. But is this picture as straightforward as it seems? Let's start with C...

As the world continues to grapple with the complexities of cancer treatment, a new wave of innovation is emerging in the form of radiopharmaceuticals. These groundbreaking medications have the potential to revolutionize the way we approach cancer care, offering a targeted and minimally invasive approach that delivers radiation directly to tumors. With a projected mar...

Eli Lilly, the pharmaceutical giant known for its diabetes and weight-loss drugs, has made a bold move by appointing insider Lucas Montarce as their new chief financial officer. This comes months after former CFO Anat Ashkenazi left to join Google parent Alphabet. Montarce brings over two decades of experience from various finance leadership roles at Lilly, including...